Immunocore Holdings (IMCR) Net Cash Flow (2021 - 2026)

Immunocore Holdings (IMCR) has reported Net Cash Flow for 6 consecutive years, with -$8.9 million the latest figure, recorded in Q1 2026.

• Quarterly Net Cash Flow fell 170.15% year-over-year to -$8.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36.3 million (up 90.02% YoY) and the FY2025 annual result came in at -$14.7 million, down 199.11% from the prior year.
• Net Cash Flow advanced to -$8.9 million in Q1 2026 per IMCR's latest filing, from -$29.3 million in the prior quarter.
• Over the last five years, Net Cash Flow for IMCR reached as high as $391.0 million in Q1 2024 and fell as low as -$327.7 million in Q2 2024.
• A 5-year average of $11.9 million and a median of $4.4 million in 2022 frame the typical range for Net Cash Flow.
• The largest YoY upside for Net Cash Flow was 2758.78% in 2024 against a maximum downside of 461.17% in 2024.
• Year by year, Net Cash Flow stood at $6.1 million in 2022, then plunged by 302.65% to -$12.3 million in 2023, then sank by 461.17% to -$69.0 million in 2024, then jumped by 57.61% to -$29.3 million in 2025, then jumped by 69.57% to -$8.9 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$8.9 million, -$29.3 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.